Regencell Bioscience (NASDAQ:RGC) Reaches New 52-Week Low – Should You Sell?

Posted by Stanley Muller on Jul 16th, 2026

Regencell Bioscience Holdings Limited (NASDAQ:RGC – Get Free Report) shares hit a new 52-week low during trading on Tuesday . The company traded as low as $4.92 and last traded at $5.05, with a volume of 474147 shares trading hands. The stock had previously closed at $5.88.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Get Our Latest Research Report on RGC

Regencell Bioscience Stock Performance

The company has a 50 day moving average price of $17.27 and a 200 day moving average price of $24.38.

Regencell Bioscience (NASDAQ:RGC – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.

Institutional Trading of Regencell Bioscience

A number of hedge funds have recently modified their holdings of RGC. Bank of America Corp DE boosted its holdings in shares of Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after buying an additional 17,143 shares during the period. Amundi bought a new position in Regencell Bioscience in the 1st quarter valued at about $219,000. Seven Fleet Capital Management LP acquired a new stake in Regencell Bioscience during the fourth quarter worth approximately $92,000. Vident Advisory LLC boosted its stake in Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares during the period. Finally, Hudson Bay Capital Management LP bought a new stake in shares of Regencell Bioscience in the fourth quarter valued at about $275,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

(Get Free Report)

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.